Posted inCosts, Health reform, Patients, Providers

15 Highest-Paid Biopharma CEOs of 2013: Follow the money

Summary: The $1,000 hepatitis C drug Sovaldi has been in the news lately for the potential dislocation to drug prices, as well as for its therapeutic benefit to hepatitis C patients. The story behind the story involves Congress planning hearings, patients begging for treatment, drug producers explaining that such high prices barely cover their costs, […]